Applications of N-Carbobenzoxy-L-Isoleucine Dicyclohexylammonium Salt in Industrial Manufacturing

N-Carbobenzoxy-L-Isoleucine Dicyclohexylammonium Salt functions as a protected amino acid derivative, commonly used in peptide synthesis workflows. This intermediate is essential for assembling high-value active molecules within pharmaceutical, biotechnology, and specialty chemical manufacturing pipelines. Downstream sectors leverage its compatibility with modern peptide synthesis strategies, ensuring process integrity and product quality.

1. Custom Peptide API Synthesis

Pharmaceutical manufacturers rely on this protected amino acid salt for segment coupling and chain elongation during solid-phase synthesis of peptide APIs. Its stable carbobenzoxy group prevents racemization and side reactions, supporting regulatory submission batches for clinical and commercial supplies.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• USP General Chapter <1045> Biological Assay Validation
• European Pharmacopoeia Monograph 01/2021:1163
• 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)

Typical usage ratio

• 15–20 mol% in protected amino acid pools, adjusted based on peptide sequence length
• Batch adjustments guided by HPLC and optical rotation results

Downstream process integration

• Introduced during resin loading and elongation stages for chain assembly
• Removes protecting groups before final cleavage and purification steps
• Validated in automated solid-phase synthesizers and parallel reactors

Final product types

• Peptide drug substances (APIs) for oncology, endocrinology, and metabolic disorders
• Peptide reference standards and analytical standards
• High-purity peptide intermediates for further modification
• Small-molecule peptide conjugates

2. Diagnostic Peptide Manufacturing

Producers of custom peptides for immunodiagnostic kits integrate this raw material for constructing short bioactive sequences. Its selectivity and solubility enable controlled stepwise protection during anti-microbial peptide or epitope synthesis. Strict internal traceability supports accreditation and lot-release documentation.

Industry compliance standards

• ISO 13485:2016 (Medical Devices—Quality Management)
• ISO 9001:2015 (Quality Management Systems)
• FDA QSR (21 CFR Part 820)
• CLSI Guideline EP25-A

Typical usage ratio

• 12–18 mol% depending on peptide length and resin capacity
• Adjusted for yield and purity, verified by LC-MS

Downstream process integration

• Applied during sequence elongation in solid or liquid-phase techniques
• Cleaved after final deprotection, followed by RP-HPLC purification
• Material traceability maintained throughout production and QC

Final product types

• Diagnostic peptides for ELISA, CLIA, and lateral flow assays
• Synthetic antigens for immunoassay development
• Synthetic peptide calibrators and controls
• MALDI-TOF peptide standards

3. Biotech R&D Peptide Libraries

Biotechnology firms utilize the protected amino acid in high-throughput combinatorial peptide library synthesis. The salt form enhances solubility and processability during code-based split-and-mix cycles. Carefully managed formulation prevents cross-contamination and supports high purity for screening campaigns.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• National Institutes of Health (NIH) Guidelines for Recombinant DNA Research
• ISO 17025:2017 (Testing and Calibration Laboratories)
• DebioPharm Peptide Synthesis Best Practices

Typical usage ratio

• 10–22 mol% per protected residue, determined by resin’s substitution value and desired library complexity
• Reviewed batchwise based on purity screening

Downstream process integration

• Dosed at each cycle of split-and-pool synthesis or automated microfluidic platform
• Deprotection prior to hit identification and fragment analysis
• Integrated with barcoding or optical tracking for sample management

Final product types

• Peptide libraries for drug discovery
• Phage display peptide pools
• Screening libraries for high-throughput screening
• Deconvoluted peptides for target validation

4. Specialty Chemical Production for Peptide Coupling Reagents

Chemical manufacturers specializing in peptide coupling agents use this protected intermediate for downstream conversion into specialty reagents. Its structure supports stable production environments and ensures minimal impurity formation, which is vital for maintaining reagent quality and reproducibility in large-scale downstream coupling operations.

Industry compliance standards

• ISO 9001:2015 (Quality Management Systems)
• REACH Regulation (EC) No 1907/2006
• Responsible Care® Management System
• EN ISO 14001:2015 (Environmental Management Systems)

Typical usage ratio

• 20–25 mol% in intermediate processing, adjusted for target reagent functionality
• Determined by reaction stoichiometry for conversion to active esters

Downstream process integration

• Charged during protected amino acid activation steps
• Contributes to synthesis of advanced coupling reagents (e.g., active esters, acid chlorides)
• Material tracked for consistent batch quality and release testing

Final product types

• Peptide coupling reagents and activating esters
• Protected amino acid building blocks
• Pre-activated peptide intermediates for third-party customers
• Custom chemical intermediates for pharma synthesis partners